Georgia's Online Cancer Information Center

Find A Doctor

Sarah Elizabeth Gill MD
Sarah Elizabeth Gill MD
Nancy N. and J.C. Lewis Cancer & Research Pavilion
https://www.sjchs.org/cancer

Sarah Elizabeth Gill MD

Specialty
Gynecology and Gynecologic Oncology
Trial Cancers
Adrenal Cancer, Bile Duct Cancer, Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Brain Tumor, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Gallbladder Cancer, Gastrointestinal Stromal Tumor (GIST), Germ Cell Tumor, Gestational trophoblastic disease, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Liver Cancer / Hepatoblastoma, Lung Cancer, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Neuroendocrine Tumor, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Parathyroid Cancer, Penile Cancer, Plasma cell neoplasm, Primary Peritoneal Cancer, Prostate Cancer , Quality of Life, Retroperitoneal Tumors, Sarcoma, Skin Cancer (Non-Melanoma), Small Bowel Cancer, Solid Tumor, Stomach/ Gastric Cancer, Testicular Cancer, Thyroid Cancer, Ureter Cancer, Urethral Cancer, Uterine Cancer
Education

Medical School: University of Tennessee College of Medicine, Memphis, TN, USA

Residency: Greenville Hospital System, Greenville, SC, USA

Fellowship: Mayo Clinic, Rochester, MN, USA

Active Clinical Trial Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Adrenal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bile Duct Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Bladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Bone Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Brain & Spinal Cord Tumor

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Brain Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Cervical Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Cervical Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Colon/Rectal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Colon/Rectal Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Esophogeal Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gallbladder Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gastrointestinal Stromal Tumor (GIST)

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Germ Cell Tumor

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gestational trophoblastic disease

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Gynecologic Cancers

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type: Gynecologic Cancers

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Cancer Type: Gynecologic Cancers

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Head and Neck Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Head and Neck Cancer

Smoke Free Support Study 2.0
Cancer Type: Hematopoietic Malignancies

Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type: Hematopoietic Malignancies

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
Cancer Type: Hematopoietic Malignancies

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Kidney Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Liver Cancer / Hepatoblastoma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Liver Cancer / Hepatoblastoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Lung Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Lung Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Lung Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Melanoma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Mesothelioma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Multiple Myeloma

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Neuroendocrine Tumor

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Ovarian Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Ovarian Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type: Ovarian Cancer

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type: Ovarian Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Cancer Type: Ovarian Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Pancreatic Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Parathyroid Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Penile Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Plasma cell neoplasm

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Plasma cell neoplasm

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type: Primary Peritoneal Cancer

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Cancer Type: Primary Peritoneal Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Retroperitoneal Tumors

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Sarcoma

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Skin Cancer (Non-Melanoma)

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Small Bowel Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Solid Tumor

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type: Solid Tumor

Smoke Free Support Study 2.0
Cancer Type: Solid Tumor

Collection of Research Data and Samples from Patients Treated with Immunotherapy to Study Its Side Effects
Cancer Type: Solid Tumor

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Stomach/ Gastric Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Stomach/ Gastric Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Testicular Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Thyroid Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Thyroid Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Unknown Primary

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Smoke Free Support Study 2.0
Cancer Type: Unknown Primary

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Cancer Type: Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Ureter Cancer

Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Cancer Type: Urethral Cancer

Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Cancer Type: Uterine Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
Cancer Type: Uterine Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.